Acetylsalicylic Acid with Ascorbate: A Promising Combination Therapy for Solid Tumors.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Cancer, particularly hepatocellular carcinoma (HCC), presents high mortality rates globally.
• Existing chemotherapeutics are often expensive and inaccessible in developing countries.
• Preclinical studies suggest acetylsalicylic acid (ASA) and ascorbate (AS) combination therapy shows promise for HCC treatment.

Purpose of the Study:

• To investigate the efficacy of combining ASA and AS in treating Ehrlich solid tumors.
• To explore the potential of this combination as a safer, more accessible cancer treatment alternative.

Main Methods:

• Eighty female Swiss albino mice were divided into healthy and Ehrlich ascites carcinoma (EAC) bearing groups.
• Mice received daily intraperitoneal injections of AS (4 g/kg) and oral ASA (60 mg/kg) for 10 days.
• Tumor burden, organ function, hematological parameters, and oxidative stress markers were assessed.

Main Results:

• Combined ASA and AS treatment significantly reduced tumor size and burden.
• The combination therapy led to increased lifespan and improved organ function.
• Treatment with ASA and AS decreased oxidative stress markers and improved lipid profiles and hemoglobin levels.

Conclusions:

• The combination of ASA and AS demonstrated significant antitumor effects against Ehrlich solid tumors.
• This combination therapy was more effective than ASA or AS alone.
• Further validation research may establish ASA and AS combination as a beneficial cancer treatment.